FDA Weighs Black Box Warning for COVID-19 Vaccines, Report Says

Federal regulators are considering adding the FDA’s most serious safety warning to COVID-19 vaccines, a move that could signal heightened concern over potential risks, according to a media report.

By yourNEWS Media Newsroom

The U.S. Food and Drug Administration is considering placing a “black box” warning on COVID-19 vaccines, according to a report published Friday that cited two people familiar with the agency’s internal deliberations.

A black box warning is the FDA’s strongest form of cautionary labeling and is used to highlight serious or potentially life-threatening risks, including severe side effects and usage restrictions.

According to the report, the effort is being overseen by Vinay Prasad, the FDA’s chief medical and scientific officer and director of the Center for Biologics Evaluation and Research, which regulates vaccines and other biological products.

The proposal has not been finalized and could still change before any formal announcement, the report said. Regulators are expected to make a decision by the end of the year, though details remain unresolved.

It is not yet clear whether the warning would apply only to messenger RNA vaccines—such as those produced by Pfizer and Moderna—or to all COVID-19 vaccines, including Novavax’s protein-based shot. The scope of the warning, including whether it would affect all age groups, also remains under discussion.

Pfizer and Moderna’s vaccines rely on mRNA technology, which instructs cells to produce a protein that triggers an immune response. Novavax’s vaccine uses a more traditional approach, delivering a purified version of the coronavirus spike protein.

Vaccine manufacturers Moderna, Pfizer, and Novavax, along with the U.S. Department of Health and Human Services, did not immediately respond to requests for comment.

The potential move would mark a significant shift in how COVID-19 vaccines are labeled and could have implications for public health guidance, prescribing practices, and public perception as federal officials continue to evaluate vaccine safety data.